Application of TRIM58 Gene Methylation-Based Minimal Residual Disease Assays in Non-Small Cell Lung Cancer for Prognosis Prediction and Treatment Decision.

This study indicates that low expression of TRIM58 may serve as a marker for poor prognosis in NSCLC patients. The low expression of TRIM58 and its promoter methylation state may be used for detecting minimal residual disease (MRD), providing new insights into early diagnosis and prognostic assessments and aiding in formulating individualized treatment strategies. Additionally, future research should increase the sample size and intensively explore the functional mechanisms of TRIM58 so as to validate its clinical application value.